We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · February 28, 2023

Serum GFAP as a Biomarker for MS Progression

JAMA Neurology


Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Neurology
Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis
JAMA Neurol 2023 Feb 06;[EPub Ahead of Print], S Meier, EAJ Willemse, S Schaedelin, J Oechtering, J Lorscheider, L Melie-Garcia, A Cagol, M Barakovic, R Galbusera, S Subramaniam, C Barro, A Abdelhak, S Thebault, L Achtnichts, P Lalive, S Müller, C Pot, A Salmen, G Disanto, C Zecca, M D'Souza, A Orleth, M Khalil, A Buchmann, R Du Pasquier, Ö Yaldizli, T Derfuss, K Berger, M Hermesdorf, H Wiendl, F Piehl, M Battaglini, U Fischer, L Kappos, C Gobbi, C Granziera, C Bridel, D Leppert, A Maleska Maceski, P Benkert, J Kuhle

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading